ATE159857T1 - Legionellosis-impfstoffe und verfahren zur herstellung - Google Patents

Legionellosis-impfstoffe und verfahren zur herstellung

Info

Publication number
ATE159857T1
ATE159857T1 AT89910005T AT89910005T ATE159857T1 AT E159857 T1 ATE159857 T1 AT E159857T1 AT 89910005 T AT89910005 T AT 89910005T AT 89910005 T AT89910005 T AT 89910005T AT E159857 T1 ATE159857 T1 AT E159857T1
Authority
AT
Austria
Prior art keywords
vaccines
pathogen
legionellosis
production
hosts
Prior art date
Application number
AT89910005T
Other languages
English (en)
Inventor
Marcus A Horwitz
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE159857T1 publication Critical patent/ATE159857T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT89910005T 1988-08-16 1989-08-15 Legionellosis-impfstoffe und verfahren zur herstellung ATE159857T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07232664 US5108745B1 (en) 1988-08-16 1988-08-16 Tuberculosis and legionellosis vaccines and methods for their production

Publications (1)

Publication Number Publication Date
ATE159857T1 true ATE159857T1 (de) 1997-11-15

Family

ID=22874048

Family Applications (2)

Application Number Title Priority Date Filing Date
AT96112524T ATE203677T1 (de) 1988-08-16 1989-08-15 Legionellosis-impfstoffe und verfahren zur deren herstellung
AT89910005T ATE159857T1 (de) 1988-08-16 1989-08-15 Legionellosis-impfstoffe und verfahren zur herstellung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT96112524T ATE203677T1 (de) 1988-08-16 1989-08-15 Legionellosis-impfstoffe und verfahren zur deren herstellung

Country Status (7)

Country Link
US (1) US5108745B1 (de)
EP (2) EP0753310B1 (de)
JP (1) JP2841094B2 (de)
AT (2) ATE203677T1 (de)
CA (1) CA1337333C (de)
DE (2) DE68929318T2 (de)
WO (1) WO1990001944A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6509151B1 (en) * 1993-09-02 2003-01-21 Cornell Research Foundation, Inc. DNA molecule encoding for cellular uptake of Mycobacterium tuberculosis and uses thereof
US6818223B2 (en) * 1993-11-23 2004-11-16 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
JPH09505588A (ja) 1993-11-23 1997-06-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 多くの細胞外生成物及びそれらの製造法並びに使用
US6752993B1 (en) 1993-11-23 2004-06-22 The Regents Of The University Of California Abundant extracellular product vaccines and methods for their production and use
US7300660B2 (en) * 1993-11-23 2007-11-27 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
NZ309945A (en) * 1995-05-23 2001-04-27 Univ California Abundant extracellular products and their use as vaccines
RU2124208C1 (ru) * 1995-06-07 1998-12-27 Государственный научный центр прикладной микробиологии Диагностикум легионеллезный и способ его получения
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6338852B1 (en) 1995-09-01 2002-01-15 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
RU2129279C1 (ru) * 1995-11-23 1999-04-20 Государственный научный центр прикладной микробиологии Диагностикум для идентификации легионелл в клиническом материале и объектах внешней среды и способ его получения
US6013660A (en) * 1996-10-02 2000-01-11 The Regents Of The University Of California Externally targeted prophylactic and chemotherapeutic method and agents
US6072048A (en) * 1997-03-10 2000-06-06 Cornell Research Foundation, Inc. DNA molecule encoding for cellular uptake of Mycobacterium tuberculosis and uses thereof
US6177086B1 (en) 1997-05-06 2001-01-23 Cornell Research Foundation, Inc. DNA molecule conferring on Mycobacterium tuberculosis resistance against antimicrobial reactive oxygen and nitrogen intermediates
US6465633B1 (en) 1998-12-24 2002-10-15 Corixa Corporation Compositions and methods of their use in the treatment, prevention and diagnosis of tuberculosis
US7083796B2 (en) * 2000-06-20 2006-08-01 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
AU4985900A (en) * 1999-05-04 2000-11-17 Public Health Research Institute Of The City Of New York, Inc., The Secreted proteins of (mycobacterium tuberculosis) and their use as vaccines and diagnostic reagents
EP1229931A4 (de) * 1999-10-07 2003-05-28 Corixa Corp Fusionsproteine aus mycobacterium tuberculosis
AU2001241738A1 (en) * 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
GB0012258D0 (en) 2000-05-19 2000-07-12 Fujitsu Ltd Transmission rate changes in communications networks
US7026465B2 (en) * 2002-02-15 2006-04-11 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis
WO2004006952A2 (en) * 2002-07-13 2004-01-22 Statens Serum Institut Therapeutic tuberculosis vaccines
US20060142251A1 (en) * 2002-11-15 2006-06-29 Gunther Harth Anti-microbial agents derived from methionine sulfoximine analogues
US7901932B2 (en) * 2005-03-17 2011-03-08 Phigenics, Llc Methods and compositions for rapidly detecting and quantifying viable Legionella
ATE536551T1 (de) * 2005-03-17 2011-12-15 Phigenics Llc Methode zum schnellen nachweisen und quantifizieren lebensfähiger legionellen
US20100015171A1 (en) 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
JP2022106353A (ja) * 2021-01-07 2022-07-20 住友金属鉱山株式会社 硫酸澱物保管容器の傾転治具

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4514509A (en) * 1981-09-21 1985-04-30 Indiana University Foundation Method for the diagnosis of Legionnaires' disease
GB8301600D0 (en) * 1983-01-21 1983-02-23 Btp Cocker Chem Ltd Control of legionella pneumophila in water systems
FR2541304A1 (fr) * 1983-02-21 1984-08-24 Centre Nat Rech Scient Anticorps monoclonaux anti-legionella, procede d'obtention et application au diagnostic de pneumonies
US4722891A (en) * 1984-06-20 1988-02-02 Board Of Regents, The University Of Texas System Methods and compositions for detection of Legionnaires' disease

Also Published As

Publication number Publication date
EP0753310A1 (de) 1997-01-15
JPH04501107A (ja) 1992-02-27
DE68928432D1 (de) 1997-12-11
EP0432203B1 (de) 1997-11-05
WO1990001944A1 (en) 1990-03-08
US5108745B1 (en) 1998-06-30
DE68928432T2 (de) 1998-03-05
DE68929318T2 (de) 2002-05-08
EP0432203A4 (en) 1991-11-06
EP0432203A1 (de) 1991-06-19
EP0753310B1 (de) 2001-08-01
CA1337333C (en) 1995-10-17
US5108745A (en) 1992-04-28
DE68929318D1 (de) 2001-09-06
JP2841094B2 (ja) 1998-12-24
ATE203677T1 (de) 2001-08-15

Similar Documents

Publication Publication Date Title
ATE159857T1 (de) Legionellosis-impfstoffe und verfahren zur herstellung
ATE127345T1 (de) Stressproteine und verwendungen dafür.
ES8203226A1 (es) Procedimiento de preparar complejos vacunantes por reaccion de arn ribonosales y de antigenos especificos.
FI113969B (fi) Menetelmä CD40:n liukoisen ligandin valmistamiseksi, sitä koodaava nukleiinihappo ja sen käyttö
ES2092306T3 (es) Adyuvante para vacunas.
ATE287947T1 (de) Orale immunisierung durch verwendung von transgenen pflanzen
ATE186461T1 (de) Verfahren zur herstellung wasserlöslicher camptothecinanaloge, sowie die verbindungen 10- hydroxy-11-c(1-6)-alkoxycamptothecin
DE3806565A1 (de) Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen
ES543026A0 (es) Un metodo para preparar una vacuna pra inducir inmunidad a la tosferina.
DK0994721T3 (da) Nervevækstfaktor som vaccineadjuvans
FI875015A0 (fi) Vaccin mot juverinflammation.
ATE273022T1 (de) Verfahren zur verstärkung zellularer immunantworten
EP0023731A3 (de) Verfahren zur Herstellung polyvalenter Virus-Impfstoffe in einem Einzelzellsystem, solche polyvalenten Impfstoffe und ihre Verwendung
FR2646776B1 (fr) Utilisation de preparations vaccinantes a base d'adenyl cyclase ou de bacteries les produisant en tant qu'antigenes protecteurs contre les effets des bordetella
DE69033833D1 (de) Verfahren zur Herstellung von Butantetracarbonsäure
DE3787121D1 (de) Verfahren zur Herstellung und Verwendung von Katzenleukämievirus-Antigenen.
AT378947B (de) Verfahren zur herstellung eines an proteinen und vitaminen reichen produktes sowie einrichtung zur durchfuehrung des verfahrens
DK0542895T3 (da) Krydsreaktiv influenza A immunisering
ATE91131T1 (de) Verfahren zum extrahieren von membranantigenen mit immunogenen eigenschaften aus humanen neoplastischen zellen und so erhaltene produkte.
DE69403197D1 (de) Die verwendung von anti-helminth impfstoffen zur kontrolle von parasitären krankheiten, die mit einem verlust der natürlichen immunität assoziiert sind
DD129805A1 (de) Verfahren zur herstellung von viruslebendimpfstoffen,insbesondere aujeszky-lebendimpfstoff
BG47346A3 (en) Method for preparing of dialkyldichlorsuccinates
WO1990015132A3 (en) Cloned treponema hyodysenteriae endoflagellar antigen
RO62730A2 (fr) Procede de preparation de vaccin vivant,attenue,de la rougeole
FI972658L (fi) Menetelmä rokotteen valmistamiseksi siipikarjan tarttuvaa bursaalitautia vastaan

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time